

REMARKS

Claims 36-37 and 62-73 are now pending.

At the outset, Applicants would like to thank the Examiner for indicating that Claims 36 and 37 are allowable. Accordingly, those claims will not be discussed further below.

Favorable reconsideration of Claims 62-73 is respectfully requested.

Claims 62-73 are directed to the recited polypeptide which is in the form of an acid addition salt, where the acid is selected from the group consisting of sulfuric acid, formic acid, citric acid, fumaric acid and maleic acid. See Claims 62, 65, 68 and 71. Each of the dependent claims further define the identity of the acid.

The rejection of the claims under 35 U.S.C. §102(e) over Seilhamer et al., U.S. 5,674,710, is respectfully traversed. That reference fails to describe the claimed polypeptide addition salts.

Seilhamer et al. describe acid addition salts where the acid is hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid or mandelic acid (see column 17, lines 47-55). The reference fails to describe acid addition salts where the acid is sulfuric acid, formic acid, citric acid, fumaric acid or maleic acid. Accordingly, Seilhamer et al. fail to disclose the claimed polypeptides. Withdraw of this ground of rejection is respectfully requested.

The rejection of the claims under 35 U.S.C. §102(e) over Seilhamer et al., U.S. 5,948,761, is respectfully traversed. That reference fails to describe the claimed polypeptide addition salts.

Seilhamer et al. describe acid addition salts where the acid is hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid or mandelic acid (see column 18, lines 13-21). The reference fails to describe acid addition salts where the acid is sulfuric acid, formic acid, citric acid, fumaric acid or maleic acid. Accordingly, Seilhamer et al. fail to

- Application No. 08/192,800
Reply to Office Action of June 2, 2004

SUPPORT FOR THE AMENDMENT

Newly-added Claims 62-73 are supported by the specification at pages 3-26 and by the original claims. No new matter is believed to have been added to the present application by the amendments submitted above.

disclose the claimed polypeptides. Withdraw of this ground of rejection is respectfully requested.

The rejection of the claims under 35 U.S.C. §102(e) over Seilhamer et al., U.S. 5,114,923, is respectfully traversed. That reference fails to describe the claimed polypeptide addition salts.

Seilhamer et al. describe acid addition salts where the acid is hydrochloric acid, phosphoric acid, acetic acid, oxalic acid, tartaric acid or mandelic acid (see column 19, lines 35-43). The reference fails to describe acid addition salts where the acid is sulfuric acid, formic acid, citric acid, fumaric acid or maleic acid. Accordingly, Seilhamer et al. fail to disclose the claimed polypeptides. Withdraw of this ground of rejection is respectfully requested.

The rejection of the claims under 35 U.S.C. §103(a) over the Seilhamer et al. patents individually or collectively and Landaburu et al., Dees et al. and Koltitschke et al. is respectfully traversed. Those references fail to suggest the claimed polypeptide addition salts.

As discussed above, the Seilhamer et al. patents fail to describe an acid addition salt where the acid is sulfuric acid, formic acid, citric acid, fumaric acid or maleic acid. There is no suggestion from those patents to use the acids recited in the claimed polypeptide addition salt.

Landaburu et al. disclose lyophilized fibronectin formulations. Dees et al. disclose an injectable pharmaceutical preparation. Koltitschke et al. disclose a coagulant plasma-protein solution. See the Abstract of each patent. None of those references individually or in any combination suggests using sulfuric acid, formic acid, citric acid, fumaric acid or maleic acid to prepare an acid addition salt of the claimed polypeptides.

Application No. 08/192,800
Reply to Office Action of June 2, 2004

In view of the foregoing, the combined disclosure of the Seilhamer et al. patents, Landaburu et al., Dees et al. and Koltitschke et al. fail to suggest the claimed polypeptides. Therefore, Claims 62-73 are not obvious over those references. Accordingly, withdraw of this ground of rejection is respectfully requested.


Applicants submit that the present application is in condition for allowance. Early notice to this effect is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/03)



James J. Kelly, Ph.D.
Attorney of Record
Registration No. 41,504